JP2010540564A - 自己相補的なａａｖが媒介する眼の障害を処置または予防するための干渉ｒｎａ分子の送達 - Google Patents
自己相補的なａａｖが媒介する眼の障害を処置または予防するための干渉ｒｎａ分子の送達 Download PDFInfo
- Publication number
- JP2010540564A JP2010540564A JP2010527251A JP2010527251A JP2010540564A JP 2010540564 A JP2010540564 A JP 2010540564A JP 2010527251 A JP2010527251 A JP 2010527251A JP 2010527251 A JP2010527251 A JP 2010527251A JP 2010540564 A JP2010540564 A JP 2010540564A
- Authority
- JP
- Japan
- Prior art keywords
- interfering rna
- eye
- scaav
- vector
- ocular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002452 interceptive effect Effects 0.000 title claims abstract description 96
- 208000022873 Ocular disease Diseases 0.000 title claims abstract description 18
- 238000012384 transportation and delivery Methods 0.000 title description 10
- 230000001404 mediated effect Effects 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 38
- 230000014509 gene expression Effects 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 239000013598 vector Substances 0.000 claims abstract description 18
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 9
- 208000030533 eye disease Diseases 0.000 claims abstract description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 108
- 239000004055 small Interfering RNA Substances 0.000 claims description 62
- 108020004459 Small interfering RNA Proteins 0.000 claims description 57
- 108020004999 messenger RNA Proteins 0.000 claims description 56
- 239000013609 scAAV vector Substances 0.000 claims description 32
- 239000007924 injection Substances 0.000 claims description 17
- 238000002347 injection Methods 0.000 claims description 17
- 206010029113 Neovascularisation Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 12
- 208000010412 Glaucoma Diseases 0.000 claims description 11
- 210000002845 virion Anatomy 0.000 claims description 8
- 239000002679 microRNA Substances 0.000 claims description 7
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
- 206010013774 Dry eye Diseases 0.000 claims description 5
- 206010030043 Ocular hypertension Diseases 0.000 claims description 4
- 108091070501 miRNA Proteins 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 239000013603 viral vector Substances 0.000 abstract description 4
- 210000001508 eye Anatomy 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 210000001585 trabecular meshwork Anatomy 0.000 description 18
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 17
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 16
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 14
- 230000009368 gene silencing by RNA Effects 0.000 description 14
- 238000003197 gene knockdown Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000004410 intraocular pressure Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 6
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000043279 ADAM17 Human genes 0.000 description 5
- 108091007505 ADAM17 Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108010048032 cyclophilin B Proteins 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 102100034608 Angiopoietin-2 Human genes 0.000 description 3
- 108050006947 CXC Chemokine Proteins 0.000 description 3
- 102000019388 CXC chemokine Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100032509 Histamine H1 receptor Human genes 0.000 description 3
- 101001016841 Homo sapiens Histamine H1 receptor Proteins 0.000 description 3
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- 102100032817 Integrin alpha-5 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 102000004070 NADPH Oxidase 4 Human genes 0.000 description 3
- 108010082699 NADPH Oxidase 4 Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102100026534 Procathepsin L Human genes 0.000 description 3
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 3
- 102100021119 Serine protease HTRA1 Human genes 0.000 description 3
- 210000002159 anterior chamber Anatomy 0.000 description 3
- -1 cationic lipid Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 210000003786 sclera Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 108010048036 Angiopoietin-2 Proteins 0.000 description 2
- 102100033040 Carbonic anhydrase 12 Human genes 0.000 description 2
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 description 2
- 101710167917 Carbonic anhydrase 2 Proteins 0.000 description 2
- 102100024644 Carbonic anhydrase 4 Human genes 0.000 description 2
- 101710167916 Carbonic anhydrase 4 Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102100038731 Chitinase-3-like protein 2 Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108010003101 ClC-3 channel Proteins 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 2
- 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100038367 Gremlin-1 Human genes 0.000 description 2
- 102100034477 H(+)/Cl(-) exchange transporter 3 Human genes 0.000 description 2
- 101000883325 Homo sapiens Chitinase-3-like protein 2 Proteins 0.000 description 2
- 101000894966 Homo sapiens Gap junction alpha-1 protein Proteins 0.000 description 2
- 101000726548 Homo sapiens Gap junction alpha-5 protein Proteins 0.000 description 2
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 description 2
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 108010041014 Integrin alpha5 Proteins 0.000 description 2
- 108010022222 Integrin beta1 Proteins 0.000 description 2
- 102000012355 Integrin beta1 Human genes 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 2
- 201000010183 Papilledema Diseases 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000012412 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 108010039230 Protein Kinase C-delta Proteins 0.000 description 2
- 102100037340 Protein kinase C delta type Human genes 0.000 description 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 2
- 208000002367 Retinal Perforations Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038886 Retinal oedema Diseases 0.000 description 2
- 206010038897 Retinal tear Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 102100025671 Solute carrier family 12 member 1 Human genes 0.000 description 2
- 108010016672 Syk Kinase Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 108010048418 alpha Subunit Hypoxia-Inducible Factor 1 Proteins 0.000 description 2
- 102000009120 alpha Subunit Hypoxia-Inducible Factor 1 Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 2
- 108010087312 carbonic anhydrase XII Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108010028075 procathepsin L Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000004844 protein turnover Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 201000011195 retinal edema Diseases 0.000 description 2
- 208000032253 retinal ischemia Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- 102000004888 Aquaporin 1 Human genes 0.000 description 1
- 108090001004 Aquaporin 1 Proteins 0.000 description 1
- 102100040794 Beta-1 adrenergic receptor Human genes 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 241000713860 FBJ murine osteosarcoma virus Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000864666 Homo sapiens ATP-dependent RNA helicase DHX8 Proteins 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 description 1
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 1
- 101000983583 Homo sapiens Procathepsin L Proteins 0.000 description 1
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 1
- 101000693078 Homo sapiens Solute carrier family 12 member 1 Proteins 0.000 description 1
- 101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 description 1
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 description 1
- 101000633069 Homo sapiens Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 description 1
- 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 description 1
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 101000806601 Homo sapiens V-type proton ATPase catalytic subunit A Proteins 0.000 description 1
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101150066553 MDR1 gene Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000047724 Member 2 Solute Carrier Family 12 Human genes 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 101710091942 N-formyl peptide receptor 2 Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710092489 Protein kinase 2 Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010089507 Proto-Oncogene Proteins c-maf Proteins 0.000 description 1
- 102000007987 Proto-Oncogene Proteins c-maf Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108091006621 SLC12A1 Proteins 0.000 description 1
- 108091006620 SLC12A2 Proteins 0.000 description 1
- 102100030058 Secreted frizzled-related protein 1 Human genes 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010074941 Sodium-Potassium-Chloride Symporters Proteins 0.000 description 1
- 102000008145 Sodium-Potassium-Chloride Symporters Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 description 1
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 description 1
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 description 1
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 102100037466 V-type proton ATPase catalytic subunit A Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 230000003263 anti-adenoviral effect Effects 0.000 description 1
- 238000011230 antibody-based therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 230000037440 gene silencing effect Effects 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940072041 transforming growth factor beta 2 Drugs 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940042596 viscoat Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97655207P | 2007-10-01 | 2007-10-01 | |
| PCT/US2008/078380 WO2009046059A1 (en) | 2007-10-01 | 2008-10-01 | Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010540564A true JP2010540564A (ja) | 2010-12-24 |
| JP2010540564A5 JP2010540564A5 (https=) | 2012-09-13 |
Family
ID=40042637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527251A Pending JP2010540564A (ja) | 2007-10-01 | 2008-10-01 | 自己相補的なａａｖが媒介する眼の障害を処置または予防するための干渉ｒｎａ分子の送達 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090087413A1 (https=) |
| EP (1) | EP2192926A1 (https=) |
| JP (1) | JP2010540564A (https=) |
| KR (1) | KR20100061792A (https=) |
| CN (1) | CN101815536A (https=) |
| AU (1) | AU2008308784B2 (https=) |
| BR (1) | BRPI0817937A2 (https=) |
| CA (1) | CA2694091A1 (https=) |
| MX (1) | MX2010001608A (https=) |
| RU (1) | RU2010117178A (https=) |
| WO (1) | WO2009046059A1 (https=) |
| ZA (1) | ZA201000423B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170054493A (ko) * | 2014-09-16 | 2017-05-17 | 젠자임 코포레이션 | 마이오실린(myoc) 녹내장을 치료하기 위한 아데노-관련 바이러스 벡터 |
| JP2021526839A (ja) * | 2018-06-12 | 2021-10-11 | ザ ユニバーシティ オブ ブリストル | 眼圧及び頭蓋内圧を調節するための材料及び方法 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2019143A1 (en) | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
| EP2058401A1 (en) | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| EP2287323A1 (en) | 2009-07-31 | 2011-02-23 | Association Institut de Myologie | Widespread gene delivery to the retina using systemic administration of AAV vectors |
| HRP20190144T1 (hr) * | 2010-04-23 | 2019-03-22 | University Of Florida Research Foundation, Inc. | Pripravci raav-gvanilat ciklaze i postupci za liječenje leberove urođene amauroze-1 (lca1) |
| CN103505743A (zh) | 2012-06-21 | 2014-01-15 | 北京命码生科科技有限公司 | 含功能性microRNA/siRNA的细胞微粒子及其应用 |
| EP4012035B1 (en) * | 2014-09-16 | 2024-11-06 | Genzyme Corporation | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
| PT4012035T (pt) * | 2014-09-16 | 2025-02-11 | Genzyme Corp | Vetores virais adenoassociados para tratar o glaucoma de miocilina (mioc) |
| AU2020361533A1 (en) | 2019-10-08 | 2022-04-28 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
| IL296103A (en) | 2020-03-05 | 2022-11-01 | Neotx Therapeutics Ltd | Methods and compositions for treating cancer with immune cells |
| WO2021245224A1 (en) * | 2020-06-05 | 2021-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating ocular diseases |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ522840A (en) * | 2000-06-01 | 2004-12-24 | Univ North Carolina | A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together |
| US20040209832A1 (en) * | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20050048529A1 (en) * | 2002-02-20 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
| US20040198682A1 (en) * | 2001-11-30 | 2004-10-07 | Mcswiggen James | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA) |
| US20060229266A1 (en) * | 2003-08-13 | 2006-10-12 | Kumar Nalin M | Silencing of tgf-beta receptor type II expression by sirna |
| WO2006042252A2 (en) * | 2004-10-08 | 2006-04-20 | Potentia Pharmeceuticals, Inc. | Viral complement control proteins for eye disorders |
| TWI401316B (zh) * | 2004-12-23 | 2013-07-11 | Alcon Inc | 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用 |
| TWI386225B (zh) * | 2004-12-23 | 2013-02-21 | Alcon Inc | 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術 |
| TW200639252A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
| KR20080018858A (ko) * | 2005-03-11 | 2008-02-28 | 알콘, 인코퍼레이티드 | 녹내장 치료용 플리즐 관련 단백질―１의 ＲＮＡⅰ－중재저해 |
| GB0521351D0 (en) * | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
| AR057252A1 (es) * | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
| TW200731980A (en) * | 2005-12-29 | 2007-09-01 | Alcon Mfg Ltd | RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis |
| TW200808360A (en) * | 2006-04-13 | 2008-02-16 | Alcon Mfg Ltd | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
| US8298818B2 (en) * | 2006-04-28 | 2012-10-30 | University Of Florida Research Foundation, Inc. | Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter |
| ES2413804T3 (es) * | 2006-05-19 | 2013-07-17 | Alcon Research, Ltd. | Inhibición mediada por ARNi de estados relacionados con factor de necrosis tumoral-alfa |
| CN102743767A (zh) * | 2006-08-24 | 2012-10-24 | 爱尔康研究有限公司 | RNAi介导的Gremlin抑制用于治疗眼内压相关的状况 |
| US7872119B2 (en) * | 2007-02-26 | 2011-01-18 | Quark Pharmaceuticals, Inc. | Inhibitors of RTP801 and their use in disease treatment |
| US7973019B1 (en) * | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
| TW200932274A (en) * | 2007-12-18 | 2009-08-01 | Alcon Res Ltd | Interfering RNA delivery system and uses thereof |
-
2008
- 2008-10-01 RU RU2010117178/15A patent/RU2010117178A/ru not_active Application Discontinuation
- 2008-10-01 MX MX2010001608A patent/MX2010001608A/es not_active Application Discontinuation
- 2008-10-01 CN CN200880110028A patent/CN101815536A/zh active Pending
- 2008-10-01 KR KR1020107003620A patent/KR20100061792A/ko not_active Withdrawn
- 2008-10-01 WO PCT/US2008/078380 patent/WO2009046059A1/en not_active Ceased
- 2008-10-01 BR BRPI0817937 patent/BRPI0817937A2/pt not_active IP Right Cessation
- 2008-10-01 CA CA2694091A patent/CA2694091A1/en not_active Abandoned
- 2008-10-01 EP EP08835867A patent/EP2192926A1/en not_active Withdrawn
- 2008-10-01 US US12/243,100 patent/US20090087413A1/en not_active Abandoned
- 2008-10-01 JP JP2010527251A patent/JP2010540564A/ja active Pending
- 2008-10-01 AU AU2008308784A patent/AU2008308784B2/en not_active Ceased
-
2010
- 2010-01-20 ZA ZA2010/00423A patent/ZA201000423B/en unknown
Non-Patent Citations (6)
| Title |
|---|
| JPN6013023940; 'Ｓｕｐｐｒｅｓｓｉｏｎ ｏｆ ｍｏｕｓｅ ｒｈｏｄｏｐｓｉｎ ｅｘｐｒｅｓｓｉｏｎ ｉｎ ｖｉｖｏ ｂｙ ＡＡＶ ｍｅｄｉａｔｅｄ ｓｉＲＮＡ ｄｅｌｉｖｅｒｙ．' Ｖｉｓｉｏｎ Ｒｅｓ． ４７（９）, 2007, １２０２-１２０８ * |
| JPN6013023942; 'Ｏｃｕｌａｒ ｇｅｎｅ ｔｒａｎｓｆｅｒ ｗｉｔｈ ｓｅｌｆ-ｃｏｍｐｌｅｍｅｎｔａｒｙ ＡＡＶ ｖｅｃｔｏｒｓ．' Ｉｎｖｅｓｔ Ｏｐｈｔｈａｌｍｏｌ Ｖｉｓ Ｓｃｉ． ４８（７）, 2007, ３３２４-３３２８ * |
| JPN6013023944; 'Ｍｅｃｈａｎｉｓｍｓ ｏｆ ＡＡＶ ｔｒａｎｓｄｕｃｔｉｏｎ ｉｎ ｇｌａｕｃｏｍａ-ａｓｓｏｃｉａｔｅｄ ｈｕｍａｎ ｔｒａｂｅｃｕｌａｒ ｍｅｓｈｗｏｒｋ ｃｅｌｌｓ．' Ｊ Ｇｅｎｅ Ｍｅｄ． ８（５）, 2006, ５８９-６０２ * |
| JPN6013023945; 'ＡＡＶ ｈｙｂｒｉｄ ｓｅｒｏｔｙｐｅｓ： ｉｍｐｒｏｖｅｄ ｖｅｃｔｏｒｓ ｆｏｒ ｇｅｎｅ ｄｅｌｉｖｅｒｙ．' Ｃｕｒｒ Ｇｅｎｅ Ｔｈｅｒ． ５（３）, 2005, ２９９-３１０ * |
| JPN6013023948; 'Ｉｎｈｉｂｉｔｉｏｎ ｏｆ Ｏｃｕｌａｒ Ａｎｇｉｏｇｅｎｅｓｉｓ ｂｙ ｓｉＲＮＡ Ｔａｒｇｅｔｉｎｇ Ｖａｓｃｕｌａｒ Ｅｎｄｏｔｈｅｌｉａｌ Ｇｒｏｗｔｈ Ｆａｃｔｏｒ Ｐａｔｈｗａｙ Ｇｅｎｅ' Ａｍ Ｊ Ｐａｔｈｏｌ． １６５（６）, 2004, ２１７７-２１８５ * |
| JPN6013023949; 'Ｐｏｔｅｎｔｉａｌ ａｐｐｌｉｃａｔｉｏｎｓ ｆｏｒ ＲＮＡｉ ｔｏ ｐｒｏｂｅ ｐａｔｈｏｇｅｎｅｓｉｓ ａｎｄ ｄｅｖｅｌｏｐ ｎｅｗ ｔｒｅａｔｍｅｎｔｓ ｆｏｒ ｏｃｕｌａｒ ｄｉｓｏｒｄｅｒ' Ｇｅｎｅ Ｔｈｅｒａｐｙ １３（６）, 2006, ５５９-５６２ * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170054493A (ko) * | 2014-09-16 | 2017-05-17 | 젠자임 코포레이션 | 마이오실린(myoc) 녹내장을 치료하기 위한 아데노-관련 바이러스 벡터 |
| JP2017529395A (ja) * | 2014-09-16 | 2017-10-05 | ジェンザイム・コーポレーション | ミオシリン（ｍｙｏｃ）緑内障を処置するためのアデノ随伴ウイルスベクター |
| KR102612871B1 (ko) | 2014-09-16 | 2023-12-13 | 젠자임 코포레이션 | 마이오실린(myoc) 녹내장을 치료하기 위한 아데노-관련 바이러스 벡터 |
| KR20230172610A (ko) * | 2014-09-16 | 2023-12-22 | 젠자임 코포레이션 | 마이오실린(myoc) 녹내장을 치료하기 위한 아데노-관련 바이러스 벡터 |
| KR102916865B1 (ko) | 2014-09-16 | 2026-01-23 | 젠자임 코포레이션 | 마이오실린(myoc) 녹내장을 치료하기 위한 아데노-관련 바이러스 벡터 |
| JP2021526839A (ja) * | 2018-06-12 | 2021-10-11 | ザ ユニバーシティ オブ ブリストル | 眼圧及び頭蓋内圧を調節するための材料及び方法 |
| JP7430917B2 (ja) | 2018-06-12 | 2024-02-14 | ザ ユニバーシティ オブ ブリストル | 眼圧及び頭蓋内圧を調節するための材料及び方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010001608A (es) | 2010-03-15 |
| US20090087413A1 (en) | 2009-04-02 |
| BRPI0817937A2 (pt) | 2015-04-07 |
| CA2694091A1 (en) | 2009-04-09 |
| RU2010117178A (ru) | 2011-11-10 |
| CN101815536A (zh) | 2010-08-25 |
| KR20100061792A (ko) | 2010-06-09 |
| ZA201000423B (en) | 2011-03-30 |
| WO2009046059A1 (en) | 2009-04-09 |
| AU2008308784A1 (en) | 2009-04-09 |
| AU2008308784B2 (en) | 2013-07-18 |
| EP2192926A1 (en) | 2010-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008308784B2 (en) | Self complementary AAV-mediated delivery of interfering RNA molecules to treat or prevent ocular disorders | |
| US10138483B2 (en) | Transferrin/transferrin receptor-mediated siRNA delivery | |
| US9526799B2 (en) | Low density lipoprotein receptor-mediated siRNA delivery | |
| US9795684B2 (en) | Interfering RNA delivery system and uses thereof | |
| US9932584B2 (en) | Interfering RNA delivery system and uses thereof | |
| JP2010501188A (ja) | ＩＯＰに関連した病態の処置のためのグレムリンのＲＮＡｉ媒介阻害 | |
| US20080214486A1 (en) | RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONS | |
| US20080171719A1 (en) | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS | |
| WO2012161677A1 (en) | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110802 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120720 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130520 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131028 |